The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $89.72

Today's change+0.34 +0.38%
Updated November 28 1:00 PM EST. Delayed by at least 15 minutes.
 

Biomarin Pharmaceutical Inc

Nasdaq: BMRN
Last

(U.S.) $89.72

Today's change+0.34 +0.38%
Updated November 28 1:00 PM EST. Delayed by at least 15 minutes.

Biomarin Pharmaceutical Inc up (U.S.)$0.34

Biomarin Pharmaceutical Inc closed up Friday by (U.S.)$0.34 or 0.38% to (U.S.)$89.72. Over the last five days, shares have gained 4.53% and are currently 1.84% off of the 52-week high. Shares have outperformed the S&P 500 by 12.44% during the last year.

Key company metrics

  • Open(U.S.) $89.47
  • Previous close(U.S.) $89.38
  • High(U.S.) $90.83
  • Low(U.S.) $88.92
  • Bid / Ask(U.S.) $89.58 / (U.S.) $90.10
  • YTD % change+27.53%
  • Volume516,328
  • Average volume (10-day)1,224,833
  • Average volume (1-month)1,113,389
  • Average volume (3-month)1,160,131
  • 52-week range(U.S.) $55.04 to (U.S.) $91.40
  • Beta0.95
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$0.88
Updated November 28 1:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-18.91%

Biomarin Pharmaceutical Inc has a net profit margin of -18.91%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX1.16%Sector:HealthcareIndustry:Pharmaceuticals - Generic & Specialty
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue177192152147
Total other revenue--------
Total revenue177192152147
Gross profit147161129122
Total cost of revenue30312325
Total operating expense166211178200
Selling / general / administrative79686071
Research & development1261088697
Depreciation / amortization11112
Interest expense (income), net operating--------
Unusual expense (income)-68103
Other operating expenses, total238-9
Operating income11-20-26-53
Interest income (expense), net non-operating-9-9-9-8
Gain (loss) on sale of assets--------
Other--------
Income before tax3-28-35-59
Income after tax7-34-38-62
Income tax, total-4633
Net income7-34-38-62
Total adjustments to net income--------
Net income before extra. items7-34-38-62
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items7-34-38-62
Inc. avail. to common incl. extra. items7-34-38-62
Diluted net income8-34-38-62
Dilution adjustment000--
Diluted weighted average shares159146144143
Diluted EPS excluding extraordinary itemsvalue per share0.05-0.23-0.26-0.43
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.23-0.23-0.26-0.42